Rani Therapeutics Holdings, Inc. - RANI
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 28, 2026 | SCHEDULE 13D/A | — | 9.9% | — | View |
| May 15, 2026 | SCHEDULE 13G/A | SymBiosis Capital Partners, LLC | 4.4% | 4,433,620 | View |
| Apr 30, 2026 | SCHEDULE 13G | Vanguard Capital Management | 5.12% | 5,109,368 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G | AWM Investment Company, Inc. | 9.9% | 9,745,343 | View |
| Feb 12, 2026 | SCHEDULE 13G | SymBiosis Capital Partners, LLC | 6.5% | 6,300,000 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.23% | 5,109,368 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.